Marina Planas: MRD and Molecular Monitoring Take Center Stage at EHA 2026
Marina Planas, CEO and Co-Founder, Chief Strategy Officer (CSO) and Board Member at Altum Sequencing, shared a post on LinkedIn:
“European Hematology Association (EHA) 2026 confirmed something we strongly believe at Altum Sequencing:
The future of hematology will be increasingly shaped by MRD and molecular monitoring.
Over the past few days in Stockholm, one theme appeared repeatedly across scientific sessions and industry discussions: the need to detect response, resistance and relapse earlier, with greater precision and actionable insights.
This year’s congress was also a special milestone for Altum Sequencing.
For the first time, we exhibited with our own stand at the European Hematology Association (EHA).
Over four intense days, we strengthened relationships with existing customers, initiated discussions with prospective customers, and met with pharmaceutical companies, clinicians, principal investigators, industry partners and technology leaders shaping the future of precision medicine.
Seeing Joaquin Martinez and Rosa Ayala at our stand, together with an exceptional Altum Sequencing team, was a powerful reminder that transformative companies are built when scientific excellence meets execution.
We return from Stockholm with new opportunities, stronger partnerships and even greater ambition.
We believe MRD and molecular monitoring will become a standard component of cancer care.
And Altum Sequencing intends to help make that future a reality.”
Stay updated with Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian